172 related articles for article (PubMed ID: 15118072)
1. Targeting targeted therapy.
Green MR
N Engl J Med; 2004 May; 350(21):2191-3. PubMed ID: 15118072
[No Abstract] [Full Text] [Related]
2. K-ras mutations in lung cancer: the "mysterious mutation".
Hirsch FR
Clin Lung Cancer; 2006 Jul; 8(1):11-2. PubMed ID: 16870039
[No Abstract] [Full Text] [Related]
3. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
[No Abstract] [Full Text] [Related]
4. Cancer. A bull's eye for targeted lung cancer therapy.
Minna JD; Gazdar AF; Sprang SR; Herz J
Science; 2004 Jun; 304(5676):1458-61. PubMed ID: 15178790
[No Abstract] [Full Text] [Related]
5. Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Kim KS; Jeong JY; Kim YC; Na KJ; Kim YH; Ahn SJ; Baek SM; Park CS; Park CM; Kim YI; Lim SC; Park KO
Clin Cancer Res; 2005 Mar; 11(6):2244-51. PubMed ID: 15788673
[TBL] [Abstract][Full Text] [Related]
6. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
[TBL] [Abstract][Full Text] [Related]
7. EGFR mutations and sensitivity to gefitinib.
Rossi G; Marchioni A; Longo L
N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15376351
[No Abstract] [Full Text] [Related]
8. [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
Lai RS; Xie L; Shen LS; He YM; Zhu CL
Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):745-6. PubMed ID: 16536324
[No Abstract] [Full Text] [Related]
9. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
[TBL] [Abstract][Full Text] [Related]
10. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Friedrich MJ
J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
[No Abstract] [Full Text] [Related]
11. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
Sequist LV; Haber DA; Lynch TJ
Clin Cancer Res; 2005 Aug; 11(16):5668-70. PubMed ID: 16115901
[No Abstract] [Full Text] [Related]
12. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
[TBL] [Abstract][Full Text] [Related]
13. [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
Madelaine J; Cadranel J; Zalcman G
Rev Mal Respir; 2004 Nov; 21(5 Pt 1):881-5. PubMed ID: 15622331
[No Abstract] [Full Text] [Related]
14. Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
Márquez-Medina D; Gasol-Cudós A; Taberner-Bonastre MT; Samamé Pérez-Vargas JC; Salud-Salvia A; Llombart-Cussac A
Arch Bronconeumol; 2013 Feb; 49(2):79-81. PubMed ID: 22627040
[TBL] [Abstract][Full Text] [Related]
15. Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.
Yang TY; Tsai CR; Chen KC; Hsu KH; Lee HM; Chang GC
J Clin Oncol; 2011 Jun; 29(16):e468-9. PubMed ID: 21422421
[No Abstract] [Full Text] [Related]
16. Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
Gazdar AF
Medicine (Baltimore); 2011 May; 90(3):168-170. PubMed ID: 21512415
[No Abstract] [Full Text] [Related]
17. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
[No Abstract] [Full Text] [Related]
18. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
[No Abstract] [Full Text] [Related]
19. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
